Day 2, Session VII

New Directions and Opportunities in Epilepsy Research, moderated by Jacqueline French, MD, Professor of Neurology, New York University


This 6 presentation and panel session includes:

  • New Directions in Epilepsy Research
    Daniel Lowenstein, MD, Robert B. and Ellinor Aird Professor and Vice-Chair of Neurology, Director, UCSF Epilepsy Center, University of California, San Francisco
    Starts at 0:32
  • The Role of Corporate and Government Partnerships in Developing New Epilepsy Products | Presentations and Panel Discussion moderated by Roger J. Porter, MD
    Starts at 33:12
    • What Does Big Pharma Look for in a New Drug for Epilepsy?
      Santiago Arroyo, MD, PhD, VP, Head of Clinical Research & CMO, Pharmatherapeutics, Worldwide Research & Development, Pfizer Inc.
      Starts at 33:47
    • What Does Big Pharma Look for in a New Drug for Epilepsy?
      Roy E. Twyman, MD, Vice President and Global Head of CNS Development, Janssen Pharmaceuticals R&D
      Starts at 42:13
    • What Does Medium Sized Epilepsy-Oriented Pharma Look for in a New Drug for Epilepsy?
      Michael Gold, MD, Vice-President and Head of the CNS Practice, UCB
      Starts at 51:46
    • What Does the Device Industry Look for When Considering Developing a New Product in the Epilepsy Space?
      Frank Fischer, CEO, NeuroPace, Inc.
      Starts at 1:04:35

<< Previous Video:
Day 1, Late-Stage and Approved Devices--What is New?, Nonprofit Organization, Government and Crowdfunding--Grants, Awards and Funding to Advance Research to the Next Critical Stage, Lifetime Accelerator Award

>> Next Video: 
Day 2, Clinical Stage Drugs

2014 Epilepsy Pipeline Conference

On June 5-7, 2014 in San Francisco, CA, the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation presented the 4th Biennial Epilepsy Pipeline Conference 2014, held at the Hyatt Regency, San Francisco.

Showcasing the most promising epilepsy therapies from healthcare companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy and seizures, this year's conference featured the third annual "Shark Tank" competition, in addition to a day designated for people with epilepsy, families and advocates. The conference brought together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation and product development. Speakers and attendees included emerging biotech and medical technology companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.

Read the press release for more information